KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Working Capital Changes (2016 - 2025)

CRISPR Therapeutics AG's Other Working Capital Changes history spans 11 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 154.18% year-over-year to $2.2 million; the TTM value through Dec 2025 reached -$397000.0, up 92.49%, while the annual FY2025 figure was -$397000.0, 92.49% up from the prior year.
  • Other Working Capital Changes for Q4 2025 was $2.2 million at CRISPR Therapeutics AG, up from -$3.3 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $22.6 million in Q4 2023 and bottomed at -$16.8 million in Q3 2023.
  • The 5-year median for Other Working Capital Changes is -$376500.0 (2022), against an average of $722944.4.
  • The largest YoY upside for Other Working Capital Changes was 9161.45% in 2023 against a maximum downside of 1420.39% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at -$4.9 million in 2021, then skyrocketed by 94.88% to -$249000.0 in 2022, then skyrocketed by 9161.45% to $22.6 million in 2023, then plummeted by 117.61% to -$4.0 million in 2024, then skyrocketed by 154.18% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Other Working Capital Changes are $2.2 million (Q4 2025), -$3.3 million (Q3 2025), and $1.6 million (Q2 2025).